Table 2.
Lipid regulating effects of statin/other drug combination treatment compared with statin monotherapy. Data show mean differences calculated from published studies19
| Dyslipidaemia phenotype | Statin (mg/day) | Other drug (mg/day) | Δ Combination v statin | ||
| LDL-C | HDL-C | TG | |||
| Hypercholesterolaemia | p 40, L 20–80 | NA 1200–3000 | −13% | +9% | −15% |
| P, F 40 | G 1200, B 400 | −8% | +9.5% | −27% | |
| Hypertriglyceridaemia | p 20, A, S, | NA 1000–3000 | −9.5% | +26% | −25.5% |
| F 5–80 | |||||
| Mixed hyperlipidaemia | p 20, S 10–20 | G 1200, B 400, f 300 | +4% | +8% | −34.5% |
A, atorvastatin; B, bezafibrate; F, fluvastatin; f, fenofibrate; G, gemfibrozil; L, lovastatin; NA, nicotinic acid; P, pravastatin; S, simvastatin.